
-
|
| |  | |  |
Research | Children's Health
|
| Flame Retardants in Placenta and Breast Milk and Cryptorchidism
in Newborn Boys Katharina Maria Main,1 Hannu Kiviranta,2
Helena Eeva Virtanen,3 Erno Sundqvist,3 Jouni
Tapio Tuomisto,2 Jouko Tuomisto,2 Terttu Vartiainen,2,4 Niels Erik
Skakkebæk,1 and Jorma Toppari1,3 1University Department of Growth and Reproduction, Rigshospitalet,
Copenhagen, Denmark; 2National Public Health Institute, Department
of Environmental Health, Kuopio, Finland; 3Departments of
Physiology and Paediatrics, University of Turku, Turku, Finland; 4University
of Kuopio, Department of Environmental Sciences, Kuopio, Finland Abstract Background: Polybrominated diphenyl ethers (PBDEs) are widely used in Western countries. Objectives: Because the prevalence of cryptorchidism appears to be increasing, we investigated whether exposure to PBDEs was associated with testicular maldescent. Methods: In a prospective Danish–Finnish study, 1997–2001, all boys were examined for cryptorchidism. We analyzed whole placentas (for 95 cryptorchid/185 healthy boys) and individual breast milk samples (62/68) for 14 PBDEs and infant serum samples for gonadotropins, sex-hormone binding globulin, testosterone, and inhibin B. Results: In 86 placenta–milk pairs, placenta PBDE concentrations in fat were lower than in breast milk, and a larger number of congeners were nondetectable. There was no significant difference between boys with and without cryptorchidism for individual congeners, the sum of 5 most prevalent, or all 14 congeners. The concentration of PBDEs in breast milk was significantly higher in boys with cryptorchidism than in controls (sum of BDEs 47, 153, 99, 100, 28, 66, and 154: median, 4.16 vs. 3.16 ng/g fat ; p < 0.007) . There was a positive correlation between the sum of PBDEs and serum luteinizing hormone (p < 0.033) . The sum of PBDEs in breast milk did not differ between Denmark and Finland (median, 3.52 vs. 3.44 ng/g fat) , but significant differences in some individual congeners were found. Conclusions: Two different proxies were used for prenatal PBDE exposure, and levels in breast milk, but not in placenta, showed an association with congenital cryptorchidism. Other environmental factors may contribute to cryptorchidism. Our observations are of concern because human exposure to PBDEs is high in some geographic areas. Key words: breast milk, cryptorchidism, exposure, human, infant, polybrominated diphenyl ethers. Environ Health Perspect 115:1519–1526 (2007) . doi:10.1289/ehp.9924 available via http://dx.doi.org/ [Online 31 May 2007] Address correspondence to K.M. Main, University Department of Growth and Reproduction, Section 5064, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Telephone: (+45) 3545-5085. Fax: (+45) 3545-6054. E-mail: katharina.main.rh.regionh.dk Children were examined by members of The Nordic Cryptorchidism Study Group: in Denmark, K.A. Boisen, M. Chellakooty, I.N. Damgaard, and I.M. Schmidt ; in Finland, M.M. Kaleva and A.-M. Suomi. This study was supported by the European Commission (QLK4-CT-1999-01422, QLK4-CT-2001-00269, QLK4-2002-0063) ; The Danish Medical Research Council (9700833, 9700909) ; the Svend Andersen's, Velux, and Novo Nordisk Foundations ; The Turku University Central Hospital ; Sigrid Jusélius Foundation ; and the Academy of Finland. The sponsors had no part in study design, data collection, analysis, interpretation, or writing of the manuscript. The article does not represent the opinion of the European Commission, which is not responsible for any use that might be made of data appearing therein. The authors declare they have no competing financial interests. Received 24 November 2006 ; accepted 30 May 2007. |
|
|
 |
Polybrominated diphenyl ethers (PBDEs) are widely
used as flame retardants, and the general population is exposed through
products such as upholstery, building materials, insulation, electronic
equipment, and contaminated food. PBDEs are added to polymers without
being chemically bound and can leach into the environment, where they
settle with air particles and sludge. They are persistent, and some—BDE-47,
BDE-99, and BDE-153—can accumulate in lipid-rich tissues (Agency
for Toxic Substances and Disease Registry 2004; Sjödin et al. 2003).
Concentrations of PBDE in human European breast
milk samples are generally low compared with those in the United States,
and considered to be well below the estimated lowest observed adverse
effect level (LOAEL) of 1 mg/kg/day (Darnerud et al. 2001). Two technical
mixtures, penta- and octa-mixtures of PBDEs, have been banned from use
in Europe since 2003 (Darnerud et al. 2001), and Swedish studies indicated
a decrease in breast milk levels since the middle of the 1990s (Meironyte
et al.1999; Sjödin et al. 2003). However, annual production rates
of some PBDEs are still considerable in some areas (Alaee et al. 2006;
Betts 2002; Law et al. 2006). Animal studies show that some PBDEs exhibit
endocrine-disrupting activity, which has been studied predominantly
for thyroid hormone transport and metabolism (Legler and Brouwer 2003),
but data on adverse effects on reproductive outcome after gestational
exposure are also emerging (Lilienthal et al. 2006).
The prevalence of cryptorchidism in newborn boys
appears to have increased in some areas, such as Great Britain and Denmark,
over the past decades, and its current prevalence is considerably higher
in Denmark than in Finland (Anonymous 1986; Boisen et al. 2004). Although
the reason for this is as yet unknown, the rapid increase in prevalence
suggests that environmental factors are involved (Sharpe 2006; Skakkebæk
et al. 2001). Adverse effects of fetal exposure to environmental chemicals
on testicular descent and hormonal function may be detectable during
the short physiologic activation of the pituitary–gonadal axis
at approximately 3 months of age (Andersson et al. 1998; Main et al.
2000, 2006b; Suomi et al. 2006).
In this study we aimed to evaluate the association
between exposure to 14 PBDEs (BDEs 28, 47, 66, 71, 75, 77, 85, 99, 100,119,
138, 153, 154, 183) in newborn boys and the position and function of
the testes.
The study was conducted according to the Helsinki
II Declaration (World Medical Association 2000) after informed oral
and written consent of the parents. The ethical committees (Finland:
7/1996; Denmark: KF01-030/97) and the Danish Data Protection Agency
(1997-1200-074) approved the study.
Study population. We obtained breast
milk samples and placentas from a joint prospective, longitudinal cohort
study performed 1997–2001 at Turku University Hospital, Turku,
Finland, and the National University Hospital (Rigshospitalet, Hvidovre
Hospital), Copenhagen, Denmark. This binational study aimed at establishing
contemporary prevalence rates for cryptorchidism and hypospadias and
evaluating risk factors by means of questionnaires and biological samples
(blood, placentas, breast milk). Exposure measurements were prospectively
planned to include persistent and nonpersistent chemicals, some of which
have been previously reported (Damgaard et al. 2006; Main et al. 2006a;
Shen et al. 2005, 2006, 2007). Recruitment strategy, inclusion criteria,
and clinical examination of the children (i.e., the identification of
cryptorchidism) have been previously described (Boisen et al. 2004;
Main et al. 2006b; Suomi et al. 2006) and were strictly standardized.
Boys with normally descended testes, including retractile testes, were
used as controls in this study under the terms "controls"
or "healthy boys." Boys with undescended testes (nonpalpable,
inguinal, suprascrotal, high scrotal), either uni- or bilaterally at
birth, were included in the group of cryptorchid boys.
All boys were examined at birth and at 3 months
of age before the results of chemical analyses were known. Birth weight
and length were obtained from hospital records. The supine length of
the children was measured with infantometers (Denmark: Kidimeter, Raven
Equipment Ltd., Essex, United Kingdom; Finland: Pedihealth Ky, Oulu,
Finland). Weight was measured on a digital scale (Baby scale model;
Solotop Oy, Helsinki, Finland). Weight for gestational age was calculated
using national standards as percent deviation from the expected mean
(Marsál et al. 1996; Pihkala et al. 1989), –22% being equivalent
to –2 SDs.
Biological samples. In Denmark biological
samples were collected from all participants (case–cohort design).
In Finland, due to lack of storage space, biological samples were collected
from boys with cryptorchidism at birth and matched controls [matching
criteria: parity, maternal smoking (yes/no), diabetes (yes/no), gestational
age (± 7 days), and date of birth (± 14 days)] as a nested
case–control design.
From this bio-bank, we selected 280 placentas (168
Danish/112 Finnish) and 130 breast milk samples (65 Danish/65 Finnish)
for PBDE measurements; this number was determined by funding. Birth
examination data were used for classification of cryptorchid and healthy
boys.
In Finland, placentas were selected from 56 case–control
pairs, in which both placentas were available. In Denmark, all available
placentas from cryptorchid boys were chosen (n = 39). Control
placentas were selected randomly from the total Danish cohort (n
= 129).
Hereafter, 65 breast milk samples were selected
for each country, with the aims, if possible, of having equal numbers
of samples from boys with and without cryptorchidism and of including
the same mothers as for placenta analyses. Only samples with a volume
> 125 mL were included to ensure that all chemicals could be analysed.
Milk from mothers of 29 cryptorchid boys and 36 randomly chosen control
boys was included in Denmark. In Finland, milk samples were chosen from
mothers of cryptorchid boys (n = 33), matched controls (n
= 18), or random controls (n = 14).
For 86 boys, milk and placentas could be selected
from the same mother–child pair (10 Danish boys with cryptorchidism,
33 Danish controls, 20 Finnish boys with cryptorchidism, 23 Finnish
controls).
Collection of samples. Whole placentas
were collected by the midwives and frozen immediately in two layers
of polyethylene bags (–20°C). Placentas were not bled before
storage.
Each mother collected one breast milk sample. We
wished to assess the average concentration of PBDEs during the period
preceding the endogenous hormone surge in infants. Thus, each sample
consisted of several small aliquots collected over successive feedings
over several weeks and frozen in household freezers in 250-mL Pyrex
glass bottles (1515/06D; Bibby Sterilin, Staffordshire, UK) with Teflon
coated caps. The mothers were instructed orally and in writing to feed
the baby, and then to sample aliquots (hind milk), beginning 1 month
after birth. We chose this start point after discussion with the ethics
committee for human subject studies to ensure that breast-feeding had
been well established. Mothers were instructed to collect samples into
a clean household glass or porcelain container, avoiding, if possible,
the use of breast pumps, and to freeze every portion immediately. Breast
milk was delivered frozen to the hospital at the 3 months' examination
and stored at –20°C. In 57 of the 65 Danish mothers, but no
Finnish mothers, information on breast pump use was obtained at sample
delivery; 26 (46%) had used a pump on one or more occasions. No information
was obtained on the type of breast pump (glass or plastic).
Blood samples. Venous nonfasting blood
samples (4 mL) were drawn from the infants at the 3 months' examination
(median age, 3.0 months; range, 2.4–4.1); the overall success
rate of obtaining a sample in the study was 74%. After clotting, the
blood samples were centrifuged and the sera were separated and stored
at –20°C. All samples were analysed as duplicates and blinded
for the technician at one laboratory (Rigshospitalet, Denmark) for reproductive
hormones. Each run contained samples of both cryptorchid and healthy
boys from both countries (up to 160 samples per analysis) to minimize
any effect of interassay variation.
Hormone analyses. We analyzed serum
follicle-stimulating hormone (FSH), luteinizing hormone (LH), and sex
hormone–binding globulin (SHBG) using time-resolved immunofluorometric
assays (Delfia, Wallac Inc., Turku, Finland). Detection limits were
0.06 and 0.05 IU/L for FSH and LH, respectively, and 0.23 nmol/L for
SHBG. The intra- and interassay coefficients of variation (CV) were
< 5% in both gonadotropin assays and < 6% for SHBG. We measured
serum testosterone by radioimmunoassay (Coat-a-Count; Diagnostic Products
Corp., Los Angeles, CA, USA), with a detection limit of 0.23 nmol/L
and intra- and interassay CVs < 10%. Free testosterone index was
calculated: (testosterone 100)/SHBG. We analyzed serum inhibin
B by a double antibody enzyme-immunometric assay (Main et al. 2006b).
The detection limit was 20 pg/mL, and intra- and interassay CVs were
< 15 % and < 18 %, respectively. Ratios between hormones were
calculated: LH/testosterone, LH/free testosterone, FSH/inhibin B.
Analysis of PBDE. All PBDE analyses
for both milk and placenta were performed at the laboratory at the Department
of Environmental Health in Kuopio, Finland. Placentas were defrosted,
and the umbilical cord and all readily removable membranes were discarded.
Whole placentas were homogenized in a mixer (Büchi Mixer B-400;
Büchi Laboratories AG, Flawil, Switzerland), and 75 g of the homogenate
was lyophilized. Dried homogenate was pulverized in a mortar and slurry
was made by adding dichloromethane and cyclohexane (1:1 vol/vol) and
concentrated sulphuric acid. This slurry was spiked with six 13C-labeled
PBDE internal standards (BDEs 28, 47, 77, 99, 153, and 183) (Wellington
Laboratories Inc., Guelph, Canada). Fat was not determined, and fat-based
results were relying on the gravimetrically measured fat contents obtained
from a German partner in this European Commission project (Shen et al.
2005, 2006, 2007).
Breast milk samples (average volume, 70 mL) were
thawed in sample bottles in a water bath (40°C) for 1 hr and homogenized.
Fat was extracted with a mixture of diethyl ether and hexane (1:1.4
vol/vol) after addition of sodium oxalate solution and ethanol (1:5
vol/vol). Fat content was determined gravimetrically after exchange
of the solvent to hexane. An average 1.5 g of fat was spiked with the
same set of internal standards used with placenta.
The procedure for decomposition of fat and sample
cleanup has been described previously (Kiviranta et al. 2004). We quantified
14 PBDE analytes (BDEs 28, 75, 71, 47, 66, 77, 100, 119, 99, 85, 154,
153, 138, and 183) by selective-ion recording using a high resolution
mass spectrometer (Autospec Ultima; Micromass Inc., Manchester, UK)
at resolution 10,000. Gas chromatographic separation of the PBDEs was
performed with a Hewlett Packard 6890 gas chromatograph with fused silica
capillary column (DB5-MS, 60 m, 0.25 mm, 0.25 µm; J&W Scientific,
Folsom, CA, USA). As a recovery standard for internal PBDE standards
polychlorinated biphenyl congener 159 was used.
In the analysis of PBDEs at the Department of Environmental
Health (National Public Health Institute, Kuopio, Finland), the technicians
and chemists were blinded. Laboratory and cross-sample contamination
was monitored by analyzing procedural blank samples. The concentrations
of these blank samples were much lower than the concentrations in placenta
and breast milk—on average, 3.6 and 2.6% of the average sum of
PBDEs in placenta and milk, respectively.
Recoveries of individual internal PBDE standards
were > 60%. Median limit of quantification (LOQ) for placentas corresponding
to a signal to noise ratio of 3:1, was 0.006 ng/g fat (range, 0.004–0.14
ng/g fat). Corresponding LOQs for breast milk were 0.004 ng/g fat (range,
0.0003–0.12 ng/g fat). In placenta, CVs for individual congeners
were 10–20%, and > 20% at concentration levels 0.1–1
ng/g fat and < 0.1 ng/g fat, respectively. In breast milk samples
corresponding values were < 10%, 10–20%, and > 20% at concentrations
levels > 1 ng/g fat, 0.1–1 ng/g fat, and < 0.1 ng/g fat,
respectively. Concentrations below the LOQ were considered to be equal
to nil (lower bound results). The laboratory has successfully participated
in interlaboratory comparison studies of PBDEs in different biological
matrices including breast milk (Becher et al. 2001; Småstuen and
Becher 2004; Småstuen and Becher 2005). The Finnish Accreditation
Service (FINAS; Espoo, Finland) has verified the competence of the laboratory
(testing laboratory T077) in performing PBDE analyses in biological
samples according to the European Standard (EN ISO/IEC 17025).
Population characteristics are given as medians
and percentiles (2.5th, 97.5th). Differences between boys with and without
cryptorchidism and between Danish and Finnish populations were analysed
by Mann-Whitney U-test. Eighty-six boys participated with both
breast milk and placenta samples.
We tested country differences for (log-transformed)
PBDE concentrations in breast milk and placenta by multiple linear regression
including maternal age, parity (1, 2 and ≥ 3) and prepregnancy
body mass index (BMI; kilograms per square meter) in the model.
Correlations between individual PBDE congener concentrations,
and between PBDE concentrations and date of childbirth within the Danish
and Finnish cohort, respectively, were tested by Spearman correlation
on nontransformed data. For each country the date of birth for the first
child was set at zero; the date of birth for all consecutive children
was then calculated as number of days elapsed since the first child
of the same country-specific cohort. This variable was applied to control
for any time trends in flame-retardant concentration in the study period
1997–2001.
We tested differences in PBDE concentrations between
boys with and without cryptorchidism in a multiple regression model,
including as covariates maternal age, parity, maternal prepregnancy
BMI, and date of childbirth within the cohort (days) to control for
factors that could affect PBDE concentrations in the sample. Prematurity
and small size for gestational age (SGA) are well-known risk factors
for cryptorchidism. Because the number of premature (5 Danish, 3 Finnish)
and SGA children (3 Danish, 1 Finnish) was small in this study, analyses
were carried out both with and without inclusion of these parameters.
Analyses were carried out only for the most abundant seven congeners
in breast milk (and their sum) and for the most abundant five congeners
in placenta.
We used multiple linear regression analysis to assess
the correlation between serum levels of reproductive hormones (log-transformed
LH, FSH, SHBG, inhibin B), square root–transformed serum testosterone
or free testosterone index, and log-transformed PBDE concentrations
in breast milk. Covariates included in these analyses were country of
origin, testicular position (cryptorchidism/control), and age at blood
sampling (months).
Results
There were no significant differences in maternal
age, reported smoking, and parity between cryptorchid and control boys
(Tables 1 and 2). Gestational age and birth weight were slightly lower
in cryptorchid Danish (but not Finnish) boys than in controls. Diabetes
was more prevalent in Finnish (but not Danish) mothers of cryptorchid
boys than in their controls, because we could not always find controls
matched by this criterion. The date of childbirth within the study period
did not differ significantly between cryptorchid boys and controls (Denmark,
p = 0.327; Finland, p = 0.949).
Table 1.

|
Table 2.

|
Table 3.

|
|
Figure 1. Sum of the 7 most prevalent PBDEs in
breast milk samples (BDEs 47, 153, 99, 100, 28, 66, 154, log-transformed values)
from Denmark and Finland in boys with cryptorchidism (n = 62, blue)
and healthy boys (n = 68, white). The box plot shows medians and interquartile
ranges.
|
|
Figure 2. Concentration (percentiles) of the sum
of all PBDEs, BDE-47, and BDE-100 (ng/g fat) in human breast milk samples
from Denmark (n = 65) and Finland (n = 65), 1997–2001.
Note the differences in absolute values in the y-axis.
|
Table 4.

|
Table 5.

|
Table 6.

|
Danish mothers were slightly older than Finnish
[30.6 years; 95% confidence interval (CI), 23.6–38.8 vs. 28.7
years; 95% CI, 21.4–39.7; p < 0.011], had a lower parity
(p < 0.033) and smoked more frequently (p < 0.04).
The prevalence of diabetes mellitus was higher among Finnish women (p
< 0.004), but BMI before pregnancy (p = 0.678) did not
differ significantly between the countries (p = 0.225).
Breast milk. Seven PBDEs were measurable
in all breast milk samples (Table 3). Median concentrations were higher
in Danish but not Finnish cryptorchid boys than in controls, reaching
statistical significance for BDEs 47, 100, 28, 66, and 154. The sum
of all seven congeners was significantly higher in cryptorchid boys
than in controls if both countries were analyzed together (p <
0.007) (Figure 1), also if prematurity and SGA were included in the
model (p < 0.035). Similar results were obtained for PBDE
expressed as nanograms per liter (data shown only for the sum of all
14 congeners; Table 3). Table 4 shows the remaining seven congeners,
which were below the detection limit in a substantial number of samples,
and the sum of all 14 congeners.
The concentrations of PBDE congeners in milk samples
showed large variations between congeners and individuals (Figure 2).
Individual congener concentrations were positively correlated with one
another (r = 0.178–0.955, p < 0.0001).
There were no significant country differences in
the sum of all congeners [Denmark, 3.52 ng/g (95% CI, 1.26–14.2)
vs. Finland, 3.44 ng/g (95% CI, 1.25–13.94), p = 0.754]
or the sum of the most prevalent seven congeners, BDEs 47, 153, 99,
100, 28, 66, and 154 [Denmark, 3.24 ng/g (95% CI, 1.26–51.1) vs.
Finland, 3.23 ng/g (95% CI, 1.26–51.0), p = 0.629]. Similar
results were obtained if we analyzed only milk samples from mothers
of healthy boys (data not shown). The estimated daily intake of PBDEs
(sum of all) for an infant at 3 months of age (median infant body weight
6.58 kg, consuming 120 mL breast milk/kg) was a median of 16 ng/kg/day
(range, 6–121 ng/kg/day). Breast milk lipid (percent wet weight)
differed significantly between the countries (mean ± SD = 2.99
± 1.38 in Denmark, 4.52 ± 1.56 in Finland; p <
0.0001). The lipid content was not significantly correlated with the
sum of PBDE congeners (data not shown).
The pattern of congener distribution differed between
the countries. BDE-28 was significantly higher in Finland than in Denmark
(p < 0.021), with a similar tendency for BDE-47 (p <
0.077), which was the most prevalent congener. BDE-153 (p <
0.0001), BDE-66 (p < 0.026), and BDE-183 (p < 0.022)
were significantly higher in Denmark than in Finland, with a similar
tendency for BDE-99 (p < 0.073). For congeners at very low
concentrations, the percentage of measurable samples was higher in Denmark
than in Finland (Table 4). There was no significant effect of breast
pump use during collection of samples on the concentration of any BDE
congener in the Danish breast milk samples.
In the Danish but not the Finnish samples, the date
of childbirth within the cohort was significantly correlated with the
concentration of BDE-154 (r = –0.346, p < 0.005),
BDE-85 (r = –0.434, p < 0.0001) and BDE-75 (r
= 0.376, p < 0.002) with similar tendencies for BDE-66
(r = –0.211, p = 0.092) and BDE-77 (r = –0.214,
p = 0.087).
Serum LH levels correlated positively with the sum
of seven PBDEs in breast milk (r = 0.218, p < 0.033)
as well as with individual congeners BDE-47 (r = 0.227, p
< 0.027), BDE-100 (r = 0.293, p < 0.004), and
BDE-154 (r = 0.203, p < 0.048). Country-specific analyses
showed significant associations between serum LH and the above listed
PBDEs and their sum for Finnish milk samples, but not Danish (data not
shown). No other reproductive hormones or their ratios were significantly
correlated with the concentration of PBDEs.
Placentas. The average levels of 14
PBDE congeners per gram fat in placentas were lower than in breast milk
(Table 5), and more samples were nondetectable. Therefore, the sum of
five congeners was used instead of the seven congeners used for milk.
This had a minor influence on the total, because the sums of the five
and the 14 congeners were very close.
The distribution of congeners resembled the distribution
in breast milk, with BDE-47 and BDE-153 constituting the main fraction
of PBDEs. There was no significant country difference for the sum of
all 14 congeners (p = 0.198) or the sum of five (BDE-47, BDE-153,
BDE-99, BDE-100, and BDE-28; p = 0.192). This was also true when
only placentas from healthy boys were analyzed (data not shown). The
concentrations of the five most prevalent congeners were positively
correlated with each other (r = 0.171–0.827, p <
0.0001). Placenta lipid content (percent wet weight) differed significantly
between the countries (mean ± SD = 1.09 ± 0.17 in Denmark,
1.21 ± 0.13 in Finland; p < 0.0001). Placenta lipid
content was not significantly correlated with the sum of PBDE congeners
(data not shown).
The date of childbirth within the cohort was significantly
correlated in the Danish placentas with the concentration of BDE-66
(r = –0.246, p < 0.001), and in the Finnish placentas
with BDE-85 (r = 0.239, p < 0.01) and BDE-153 (r
= 0.275, p < 0.003).
There was no significant difference in the placenta
concentration of the five most prevalent PBDEs between cryptorchid boys
and healthy boys in Denmark (p = 0.10–0.976) or Finland
(p = 0.09–0.835) or for their sum (p = 0.312 and
p = 0.128, respectively). The results remained nonsignificant
if prematurity and SGA were included in the model. There were no correlations
between placental PBDEs and serum reproductive hormones in 3-month-old
infants.
Paired samples. The median concentrations
(nanograms per gram fat) of the 14 congeners in placenta were lower
than the concentration found in the paired breast milk samples (n
= 86) (Table 6), but there were significant correlations between
the measurements, except for BDE-85 and BDE-138.
The sum of all congeners in milk was 3.39 (95% CI,
1.43–48.2) for boys with cryptorchidism and 3.15 (95% CI, 1.07–24.9)
for controls (p = 0.228), and in placenta 1.22 (95% CI, 0.64–9.32)
for boys with cryptorchidism and 1.17 (95% CI, 0.49–5.46) for
controls (p = 0.871). Infant reproductive hormones at 3 months
of age (27 Danish, 35 Finnish boys) were not correlated to PBDE concentrations
in placenta or milk in this data subset.
To our knowledge, this is the first study describing
an association between congenital cryptorchidism in humans and exposure
to PBDEs. An association was found for the sum of seven PBDEs (BDEs
47, 153, 99, 100, 28, 66, 154) in breast milk as well as for the individual
congeners BDEs 47, 100, 28, 66, and 154. Concentrations of BDEs 47,
100, and 154 were also positively correlated with increasing serum LH
values. This suggested that a higher gonadotropin drive was necessary
to ensure normal testosterone production by the Leydig cells (Suomi
et al. 2006), and thus a subtle primary testicular disfunction.
In this study we assessed infant exposure by measuring
the concentration of PBDEs in breast milk, which reflects the accumulated
body burden of the mother (Inoue et al. 2006; Jensen and Slorach 1991;
Waliszewski et al. 2001). It also is a proxy for prenatal fetal exposure
because PBDEs, especially the lower brominated compounds, can cross
the placenta (Bi et al. 2006; Mazdai et al. 2003) and are transferred
to breast milk during lactation (Darnerud and Risberg 2006). However,
when we assesssed exposure by measuring PBDE in placenta, the results
did not support the above findings, despite the fact that 86 mother–child
pairs were represented with both milk and placenta samples. At present,
it is not clear why this is the case.
The concentration of all PBDE congeners per gram
fat in placenta was considerably lower than in milk, and more congeners
were nondetectable. These differences did not have any remarkable influence
on analytical errors, because the amount of fat used for analysis was
similar for placentas and milk samples. In theory, placenta should be
a better proxy for fetal exposure than breast milk, because it represents
the direct route of chemical transfer during pregnancy. The number of
placentas analyzed in this study was larger than the number of milk
samples, and should thus better represent the pool of cases and controls.
We could not establish any obvious selection bias of milk donors. On
the other hand, due to higher concentrations, milk analyses were somewhat
more reliable toward the lower end of concentration. This should not
be important, because the main group differences were seen at the higher
end of PBDE concentrations. It is currently unknown whether PBDEs accumulate
in placenta, but our paired samples indicated that this may not be the
case. We found positive correlations between measurements in placenta
and breast milk, but three to four times lower absolute concentrations
in placenta. Placenta concentrations may resemble measurements in single
blood samples, and thus reflect the situation at delivery but not the
long-term exposure.
There is some controversy as to whether the placental
transport of PBDEs may differ between lower and higher brominated PBDEs.
An American study reported a strong correlation of lipid-adjusted BDE
concentrations in maternal serum at term and cord blood (Mazdai et al.
2003), whereas studies from countries with a generally lower exposure
level found weaker correlations and higher values in maternal than in
fetal samples (Bi et al. 2006). Segregation from serum into breast milk
samples did not always follow a 1:1 pattern. The congener distribution
appeared to be similar for lower brominated BDEs (Bi et al. 2006; Mazdai
et al. 2003), whereas higher brominated BDEs such as BDE-209 were 10
times higher in serum than in breast milk (Inoue et al. 2006). Thus,
the relative distribution of congeners between placenta and breast milk
may also depend on the fat composition of these two matrices causing
different solubility. We found significantly higher fat concentrations
in the Finnish than in the Danish samples, which may reflect dietary
habits in the two countries, because both long-term and short-term diet
as well as the nutritional status may influence content and composition
of breast milk lipids (Ortiz-Olaya et al.1996).
Current knowledge about human reproductive health
consequences after exposure to PBDEs is very limited (Agency for Toxic
Substances and Disease Registry 2004). A study from Taiwan showed an
association between the sum of 12 PBDE congeners in breast milk, 10
of which were the same as in our study, and lower birth weight and length
(Chao et al. 2007). Recently, a Swedish case–control study found
higher values of PBDEs (sum of BDEs 47, 153, and 99) in blood samples
from mothers of young men with testicular cancer than in age-matched
controls (Hardell et al. 2006). However, maternal PBDE exposure was
assessed 15–25 years after the critical time period—that
is, at the time of the cancer diagnosis—which considerably weakens
the possibility to establish a causal link between exposure and outcome.
Also in this study (Hardell et al. 2006), exposures to other persistent
chemicals occurred simultaneously, and it cannot be determined how these
substances interact in their effect on reproductive development. Testicular
cancer is the most severe clinical symptom of the testicular dysgenesis
syndrome (TDS), which also encompasses impaired semen quality, congenital
cryptorchidism, and hypospadias (Skakkebæk et al. 2001). TDS may
be caused by genetic, hormonal, or environmental factors (Sharpe 2006;
Skakkebæk et al. 2001). Prenatal exposure to PBDEs may have an
adverse effect on testicular growth and differentiation in utero.
In animal studies, penta-brominated PBDEs showed
antiandrogenic activity (Stoker et al. 2005). A peripubertal single-dose
exposure to a commercial mixture of penta-BDEs delayed the onset of
puberty in male and female rats (Stoker et al. 2004) and suppressed
the growth of the seminal vesicles and ventral prostate. In adult rats,
a single-dose exposure significantly increased LH concentration in serum
(Stoker et al. 2005). Our observation of an association between PBDE
levels in breast milk and serum LH in infants at 3 months of age is
in line with these animal data. Gestational exposure of rats to BDE-99
caused a shortening of the anogenital distance in male and female rats,
reduction in primordial and secondary ovarian follicles, a lower sperm
count, and lower estradiol and testosterone levels in adulthood (Kuriyama
et al. 2005; Lilienthal et al. 2006). In vitro assays showed
a competitive androgen receptor binding for BDEs 47, 99, and 100. BDEs
47, 71, and 100 inhibited dihydrotestosterone-induced transcriptional
activity (Stoker et al. 2005). Because testicular descent is highly
androgen-dependent (Toppari 2003), the adverse effect of PBDE on testicular
descent could be caused by their antiandrogenic properties.
In addition, BDEs 47, 100, 75, and 51, particularly
their hydroxylated metabolites, are weakly estrogenic, and BDEs 153,
166, and 190 are antiestrogenic in vitro (Legler and Brouwer
2003; Meerts et al. 2001). Exposure of female rats to BDE-99 led to
the formation of abundant vesicles and vacuolization of the ovary (Talsness
et al. 2005), which showed signs of compromised steroidogenesis. Prenatal
female exposure to BDE-99 in rats affected estrogen target genes in
the uterus (Ceccatelli et al. 2006). Thus, the delicate balance between
androgens and estrogens in the fetus may become altered by PBDE exposure.
In mice, the metabolism of BDE-47 was highly dependent on the developmental
stage of the animal, being slowest in pups (Staskal et al. 2006). Whether
this also plays a role for human fetal development is currently unknown.
Most exposure doses used in animal studies are several orders of magnitude
higher than the levels of PBDEs found in breast milk in our study. However,
there is emerging evidence that also low-dose exposure to, for example,
BDE-99 close to levels found in human adipose tissue may have an adverse
effect on the reproductive health of the offspring (Anonymous 2005;
Kuriyama et al. 2005).
The distribution pattern of BDE congeners in breast
milk corresponded to the distribution of BDE congeners in commercially
available mixtures of PBDEs (Alaee et al. 2006; Darnerud et al. 2001;
Law et al. 2006; Lilienthal et al. 2006). The absolute concentrations
found in our study are within the same order of magnitude as reported
from other Nordic and European countries (Jaraczewska et al. 2006; Kalantzi
et al. 2004; Lind et al. 2003; Strandman et al. 2000) as well as China
(Bi et al. 2006) and Japan (Eslami et al. 2006; Inoue et al. 2006).
There are, however, significant geographic differences between and within
these countries, which point toward differences in general contamination
levels. In our study, the total amount of PBDEs did not differ between
Finnish and Danish milk or placenta samples, but the pattern of congener
distribution varied, which indicated different sources and timing of
exposure. PBDE levels reported from American studies of breast milk
appear to be considerably higher (Betts 2002). In contrast, the previous
exponential increase in penta-PBDEs in Swedish breast milk samples since
the 1970s has reversed since the late 1990s (Law et al. 2006; Meironyte
et al. 1999; Sjödin et al. 2003), when penta-BDEs were gradually
phased out. The collection of breast milk samples in our study covered
a 5-year period, and we found a negative correlation between the level
of PBDEs in breast milk and the infant date of birth. This is in line
with the expected decline in the use of penta-PBDEs in the two regions.
The high variability in PBDE concentrations among individual mothers
has been described also for other human matrices (McDonald 2002), and
may reflect variability in both exposure and metabolism. Deca-BDE can
be converted through sunlight exposure into lower brominated BDEs, which
are more readily absorbed from the intestine and bioaccumulate due to
their longer half-life than deca-BDE (Watanabe and Tatsukawa 1987).
However, it is as yet unknown how much this process contributes to human
environmental exposure to lower brominated PBDEs.
Exposure to PBDEs cannot explain the observed geographic
difference in the prevalence of cryptorchidism between Denmark and Finland.
Breast milk contains significant levels of other persistent and nonpersistent
chemical compounds (Damgaard et al. 2006; Main et al. 2006a), which
can affect perinatal testicular development. Mothers with high levels
of PBDE exposure also may be exposed to high levels of other persistent
chemicals. Thus, the combined exposure to multiple environmental factors
may cause the association between congenital cryptorchidism and PBDE
concentration in breast milk (Koppe et al. 2006). In addition, other
lifestyle factors and genetic susceptibility may play a role (Damgaard
et al. 2007; Sharpe 2006; Virtanen et al. 2006). In our total study
population, the geographic difference in the prevalence of cryptorchidism
was observed mainly for mild forms of undescended testes, which had
a high degree of spontaneous postnatal descent (Boisen et al. 2004).
This pattern was also seen in this subpopulation, in which PBDEs was
analyzed. However, also mild and transient forms of cryptorchidism are
associated with a subtle impairment of primary testicular function (Suomi
et al. 2006).
In conclusion, we used two different biological
matrices in this study to assess infant perinatal exposure. Breast milk,
but not placenta, showed an association with congenital cryptorchidism.
There are valid arguments for either matrix, and risk assessment will
require more scrutiny. The association between PBDE contamination levels
in breast milk and congenital cryptorchidism is still of concern because
exposure to PBDEs is considerable in some areas.
|
|
 |
| [References Listed in PubMed]
References
Agency for Toxic Substances and Disease Registry.
2004. Toxicological Profile for Polybrominated Biphenyls and Polybrominated
Diphenyl Ethers (PBBs and PBDEs). Available: www.atsdr.cdc.gov/toxprofiles/tp68.html
[accessed 30 March 2007]
Alaee M, Arias P, Sjödin A, Bergman A. 2006.
An overview of commercially used brominated flame-retardants, their
application, their use in different countries/regions and possible modes
of release. Environ Int 29: 683–689
Andersson A-M, Toppari J, Haavisto A-M, Petersen
JH, Simell T, Simell O, et al. 1998. Longitudinal reproductive hormone
profiles in infants: peak of inhibin B levels in infant boys exceeds
levels in adult men. J Clin Endocrinol Metab 83:675–681.
[Anonymous]. 1986. Cryptorchidism: an apparent substantial
increase since 1960. John Radcliffe Hospital Cryptorchidism Study Group.
BMJ 293:1401–1404.
[Anonymous]. 2005. Polybrominated diphenyl ether
levels among United States residents: daily intake and risk of harm
to the developing brain and reproductive organs. Integr Environ Assess
Manag 1: 343–354.
Becher G, Nicolaysen T, Thomsen C. 2001. Interlaboratory
Comparison on Dioxins in Food 2001. Final Report 4. Oslo, Norway:Folkehelsa.
Betts K. 2002. Rapidly rising PBDE levels in North
America. Environ Sci Technol 36:50A–52A.
Bi X, Qy W, Sheng G, Zhang W, Mau B, Chen D, et
al. 2006. Polybrominated diphenyl ethers in South China, maternal and
fetal blood and breast milk. Environ Pollut 144: 1024–1030.
Boisen KA, Kaleva M, Main KM, Virtanen HE, Haavisto
A-M, Schmidt IM, et al. 2004. Difference in prevalence of congenital
cryptorchidism in infants between two Nordic countries. Lancet 363:1264–1269.
Ceccatelli R, Faass O, Schlumpf M, Lichtensteiger
W. 2006. Gene expression and estrogen sensitivity in rat uterus after
developmental exposure to the polybrominated diphenyl ether PBDE-99
and PCB. Toxicology 220: 104–116.
Chao HR, Wang SL, Lee WJ, Wang YF, Papke O. 2007.
Levels of polybrominated diphenyl ethers (PBDEs) in breast milk from
central Taiwan and their relation to infant birth outcome and maternal
menstruation effects. Environ Int 33: 239–245.
Damgaard IN, Jensen TK, Petersen JH, Skakkebæk
NE, Toppari T, Main KM. 2007. Cryptorchidism and maternal alcohol consumption
during pregnancy. Environ Health Perspect 115:272–277.
Damgaard IN, Skakkebaek NE, Toppari J, Virtanen
HE, Shen H, Schramm KW, et al. 2006. Persistent pesticides in human
breast milk and cryptorchidism. Environ Health Perspect 114:1133–1138.
Darnerud PO, Eriksen GS, Johannesson T, Larsen PB,
Viluksela M. 2001. Polybrominated diphenyl ethers: occurrence, dietary
exposure and toxicology. Environ Health Perspect 109(suppl 1):49–68.
Darnerud PO, Risberg S. 2006. Tissue localization
of tetra- and pentabromodiphenyl ether congeners (BDE-47, 85 and -99)
in perinatal and adult C57BL mice. Chemosphere 62:485–493.
Eslami B, Koizumi A, Ohta S, Inoue K, Aozasa O,
Harad K, et al. 2006. Large-scale evaluation of the current level of
polybrominated diphenyl ethers (PBDEs) in breast milk from 13 regions
of Japan. Chemosphere 63: 554–561.
Hardell L, van Bavel B, Lindstrom G, Eriksson M,
Carlberg M. 2006. In utero exposure to persistent organic
pollutants in relation to testicular cancer risk. Int J Androl 29:228–234.
Inoue K, Harada K, Takenaka K, Uehara S, Kono M,
Shimizu T, et al. 2006. Levels and concentration of polychlorinated
biphenyls and polybrominated diphenyl ethers in serum and breast milk
in Japanese mothers. Environ Health Perspect 114:1179–1185.
Jaraczewska K, Lulek J, Cobaci A, Voorspoels S,
Kaluba-Skotarczak A, Drews K, et al. 2006. Distribution of polychlorinated
biphenyls, organochlorine pesticides and polybrominated diphenyl ethers
in human umbilical cord serum, maternal serum and milk from Wielkopolska
region, Poland. Sci Total Environ 372:20–31.
Jensen AA, Slorach SA. 1991. Chemical Contaminants
in Human Milk. Boston, MA:CRC Press.
Kalantzi OL, Martin FL, Thomas GO, Alcock RE, Tang
HR, Drury SC, et al. 2004. Different levels of polybrominated diphenyl
ethers (PBDEs) and chlorinated compounds in breast milk from two U.K.
regions. Environ Health Perspect 112:1085–1091.
Kiviranta H, Ovaskainen ML, Vartiainen T. 2004.
Market basket study on dietary intake of OCDD/Fs, PCBs and PBDEs in
Finland. Environ Int 30:923–932.
Koppe JG, Bartonova A, Bolte G, Bistrup ML, Busby
C, Butter M, et al. 2006. Exposure to multiple environmental agents
and their effect. Acta Paediatr (Suppl) 95: 106–113.
Kuriyama SN, Talsness CE, Grote K, Chahoud I. 2005.
Developmental exposure to low dose PBDE-99: effects on male fertility
and neurobehaviour in rat offspring. Environ Health Perspect 113:149–154.
Law RJ, Allchin CR, de Boer J, Covaci A, Herzke
D, Lepom P, et al. 2006. Levels and trends of brominated flame-retardants
in the European environment. Chemosphere 64: 187–208.
Legler J, Brouwer A. 2003. Are brominated flame-retardants
endocrine disrupters? Environ Int 29: 879–885.
Lilienthal H, Hack A, Roth-Härer A, Wichert
Grande S, Talsness CE. 2006. Effects of developmental exposure to 2,2'4,4',5-pentabromodiphenyl
ether (PBDE-99) on sex steroids, sexual development, and sexually dimorphic
behavior in rats. Environ Health Perspect 114: 194–201.
Lind Y, Darnerud PO, Atuma S, Aune M, Becker W,
Bjerselius R, et al. 2003. Polybrominated diphenyl esters in breast
milk from Uppsala County, Sweden. Environ Res 93:186–194.
Main KM, Mortensen GK, Kaleva M, Boisen K, Damgaard
I, Chellakooty M, et al. 2006a. Human breast milk contamination with
phthalates and alterations of endogenous reproductive hormones in 3-month-old
infants. Environ Health Perspect 114:270–276.
Main KM, Schmith IM, Skakkebæk NE. 2000. A
possible role for reproductive hormones in newborn boys: progressive
hypogonadism without the postnatal testosterone peak. J Clin Endocrinol
Metab 85:4905–4907.
Main KM, Toppari J, Suomi AM, Kaleva M, Chellakooty
M, Schmidt IM, et al. 2006b. Larger testes and higher inhibin B levels
in Finnish than in Danish newborn boys. J Clin Endocrinol Metab 91:2732–2737.
Marsál K, Persson PH, Larsen T, Lilja H,
Selbing A, Sultan B. 1996. Intrauterine growth curves based on ultrasonically
estimated fetal weights. Acta Paediatr 85:843–848.
Mazdai A, Dodder NG, Anernathy MP, Hites RA, Bigsby
RM. 2003. Polybrominated diphenyl ethers in maternal and fetal blood
samples. Environ Health Perspect 111: 1249–1252.
McDonald TA. 2002. A perspective on the potential
health risks of PBDEs. Chemosphere 46:745–755.
Meerts IA, Letcher RJ, Hoving S, Marsh G, Bergman
A, Lemmen JG, et al. 2001. In vitro estrogenicity of polybrominated
diphenyl ethers, hydroxylated PBDEs, and polybrominated bisphenol A
compounds. Environ Health Perspect 109:399–407.
Meironyte D, Noren K, Bergman A. 1999. Analysis
of polybrominated diphenyl ethers in Swedish human milk. A time-related
trend study, 1972–1997. J Toxicol Environ Health A 58:329–341.
Ortiz-Olaya N, Flores ME, De Santiago S. 1996 Significance
of lipid consumption during lactation. Rev Invest Clin 48:473–478.
Pihkala J, Hakala T, Voutilainen P, Raivio K. 1989.
Characteristic of recent fetal growth curves in Finland. Duodecim 105:1540–1546.
Sharpe RM. 2006. Pathways of endocrine disruption
during male sexual differentiation and masculinization. Best Pract Res
Clin Endocrinol Metab 20: 91–110.
Shen H, Main KM, Kaleva M, Virtanen H, Haavisto
AM, Skakkebæk NE, et al. 2005. Prenatal organochlorine pesticides
in placentas from Finland: exposure of male infants born during 1997–2001.
Placenta 26: 512–514.
Shen H, Main KM, Virtanen HE, Damgaard IN, Haavisto
AM, Kaleva M, et al. 2007. From mother to child: investigation of prenatal
and postnatal exposure to persistent bioaccumulating toxicants using
breast milk and placenta biomonitoring. Chemosphere 67:S256–S262.
Shen H, Virtanen HE, Main KM, Kaleva M, Andersson
AM, Skakkebæk NE, et al. 2006. Enantiomeric rations as an indicator
of exposure processes for persistent pollutants in human placentas.
Chemosphere 62:390–395.
Sjödin A, Patterson DGJr, Bergman A. 2003.
A review on human exposure to brominated flame-retardants—particularly
polybrominated diphenyl ethers. Environ Int 29:829–839.
Skakkebæk NE, Rajpert-De Meyts E, Main KM.
2001.Testicular dysgenesis syndrome: an increasingly common developmental
disorder with environmental aspects. Hum Reprod 16:972–978.
Småstuen Haug L, Becher G. 2004. Interlaboratory
Comparison on Dioxins in Food 2004. Fifth Round of An International
Study. Oslo, Norway:Norwegian Institute of Public Health.
Småstuen Haug L, Becher G. 2005. Interlaboratory
Comparison on Dioxins in Food 2005. Sixth Round of An International
Study. Oslo, Norway:Norwegian Institute of Public Health.
Staskal DF, Diliberto JJ, Birnbaum LS. 2006. Disposition
of BDE 47 in developing mice. Toxicol Sci 90: 309–316.
Stoker TE, Cooper RL, Lambright VS, Wilson F, Gray
LE. 2005. In vivo and in vitro anti-androgenic effects
of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture.
Toxicol Appl Pharmacol 207:78–88.
Stoker TE, Laws SC, Crofton KM, Hedge JM, Ferrell
JM, Cooper RL. 2004. Assessment of DE-71, a commercial polybrominated
diphenyl ether (PBDE) mixture in the EDSP male and female pubertal protocols.
Toxicol Sci 78:144–155.
Strandman T, Koistinen J, Variainen T. 2000. Levels
of some polybrominated diphenyl ethers (PBDEs) in placenta and human
milk. Organohalogen Compounds 47: 61–64.
Suomi A-M, Main KM, Kaleva M, Schmidt IM, Chellakooty
M, Virtanen HE, et al. 2006. Hormonal changes in 3-month-old cryptorchid
boys. J Clin Endocrinol Metab 91: 953–958.
Talsness CE, Shakibaei N, Kuriyama SN, Grande SW,
Sterner-Kock A, Schnitker P, et al. 2005. Ultra structural changes observed
in rat ovaries following in utero and lactational exposure
to low doses of a polybrominated flame retardant. Toxicol Lett 157:189–202.
Toppari J. 2003. Physiology and disorders of testicular
descent. Endocr Dev 5:104–109.
Virtanen HE, Tapanainen AE, Kaleva MM, Suomi AM,
Main KM, Skakkebæk NE, et al. 2006. Mild gestational diabetes
as a risk factor for congenital cryptorchidism. J Clin Endocrinol Metab
91:4862–4865.
Waliszewski SM, Aquirre AA, Infanzon RM, Silva CS,
Siliceo J. 2001. Organochlorine pesticide levels in maternal adipose
tissue, maternal blood serum, umbilical blood serum, and milk from inhabitants
of Veracruz, Mexico. Arch Environ Contam Toxicol 40:432–438.
Watanabe I, Tatsukawa R. 1987. Formation of brominated
dibenzofurans from the photolysis of flame-retardant deca-bromodiphenyl
ether in hexane solution by UV and sunlight. Bull Environ Contam Toxicol
39:953–959.
World Medical Association. 2000. Declaration of
Helsinki: Ethical principles for medical research involving human subjects.
Bull Med Eth 162:8-11.
Last Updated: September 26, 2007
|
|
 |
|
| |